Dividend Information About Medtronic: Everything You Need to Know Before the Ex-Dividend Date on Sep 26, 2025
Generado por agente de IAAinvest Dividend Digest
martes, 23 de septiembre de 2025, 7:09 am ET1 min de lectura
MDT--
Medtronic (MDT) has announced its upcoming cash dividend of $0.7100 per share, marking a notable increase compared to the average of the last 10 dividends, which stood at $0.5565. The ex-dividend date for this distribution is set for Sep 26, 2025, meaning that investors must purchase the stock before this date to qualify for the dividend. Investors will receive the dividend on Oct 17, 2025. The dividend was officially announced on Aug 14, 2025, reaffirming the company’s consistent approach to shareholder returns. The most recent dividend was paid on Jul 11, 2025, at the same rate of $0.7100 per share, also in the form of a cash dividend. This pattern reflects Medtronic’s commitment to maintaining a stable and growing dividend for its shareholders.
Over the past week, MedtronicMDT-- has remained in the spotlight with several key developments. Most recently, the company secured FDA approval for the Altaviva™ device, designed to treat urge urinary incontinence, marking a significant milestone in its product pipeline and potential long-term revenue growth. This approval has sparked renewed interest in the company’s innovation strategy, as it continues to expand its neuromodulation offerings. Additionally, Revisor Wealth Management LLC has significantly boosted its holdings in Medtronic by 164.9% during the second quarter, signaling strong confidence in the company’s strategic direction and long-term value. Analysts have noted that this surge in institutional buying could indicate a broader trend of increased investor optimism.
Since the last update, Medtronic’s stock has seen modest fluctuations. As of Sept 22, 2025, the stock price was reported at $94.62, reflecting a mix of market conditions and investor sentiment. While short-term volatility is to be expected, the company’s recent product approvals and strong institutional backing suggest that its fundamentals remain robust. Medtronic continues to position itself as one of the most profitable and innovative players in the global medical device industry, with a clear focus on high-margin product lines and strategic acquisitions.
With the ex-dividend date set for Sep 26, 2025, investors should be aware that any purchase of Medtronic stock after this date will not qualify for the upcoming dividend payment. Those looking to receive the $0.7100 per share payout must ensure their ownership is confirmed by the ex-dividend cutoff. As the company continues to make strides in both product development and financial performance, Medtronic remains a compelling option for investors seeking both stability and growth in the healthcare sector.
Over the past week, MedtronicMDT-- has remained in the spotlight with several key developments. Most recently, the company secured FDA approval for the Altaviva™ device, designed to treat urge urinary incontinence, marking a significant milestone in its product pipeline and potential long-term revenue growth. This approval has sparked renewed interest in the company’s innovation strategy, as it continues to expand its neuromodulation offerings. Additionally, Revisor Wealth Management LLC has significantly boosted its holdings in Medtronic by 164.9% during the second quarter, signaling strong confidence in the company’s strategic direction and long-term value. Analysts have noted that this surge in institutional buying could indicate a broader trend of increased investor optimism.
Since the last update, Medtronic’s stock has seen modest fluctuations. As of Sept 22, 2025, the stock price was reported at $94.62, reflecting a mix of market conditions and investor sentiment. While short-term volatility is to be expected, the company’s recent product approvals and strong institutional backing suggest that its fundamentals remain robust. Medtronic continues to position itself as one of the most profitable and innovative players in the global medical device industry, with a clear focus on high-margin product lines and strategic acquisitions.
With the ex-dividend date set for Sep 26, 2025, investors should be aware that any purchase of Medtronic stock after this date will not qualify for the upcoming dividend payment. Those looking to receive the $0.7100 per share payout must ensure their ownership is confirmed by the ex-dividend cutoff. As the company continues to make strides in both product development and financial performance, Medtronic remains a compelling option for investors seeking both stability and growth in the healthcare sector.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios